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Introduction
The overall incidence of glioma ranges from about 30-60% of all intracranial primary tumors. Glioblastoma multiforme (GBM), one of the most malignant forms of glioma, accounts for about 10% of all types of glioma. 1 The growth of glioblastomas is usually limited to the brain and the involvement of other organs is quite rare. However, the rapid migration of glioblastomas into normal brain parenchyma followed by their rapid growth results in a median life expectancy of about only 1 year. Combined treatment such as surgery, radiation therapy, chemotherapy and immunotherapy have been employed, but the clinical results so far have been far from satisfactory. Thus, novel approaches must be sought and developed if we are to expect a significant improvement in the overall survival rate of patients with GBM.
Gene therapy could provide an innovative therapeutic approach for the treatment of GBM. One of the most promising approaches is the use of retroviral vectors to mediate the delivery of suicide genes into malignant cells, a procedure that would make them sensitive to normally nontoxic prodrugs. 2 As retroviruses only integrate into mitotically active cells, the transduction of a suicide gene, such as the herpes simplex virus thymidine kinase (HTK) gene, 3 by means of a retrovirus provides a way specifically to target and kill the malignant cells. Clinical
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Received 26 February 1998; accepted 24 July 1998 trials of implantation of virus-producing fibroblasts, which produce recombinant retroviral particles containing the HTK gene, have recently been carried out at the National Institute of Health. 4, 5 Severe adverse effects were not observed, but the results of the clinical study were not as satisfactory as those obtained using experimental animal models.
The strategy failed because of the physical restrictions of the system: (1) the producer cells were non-motile, so continuous transduction of the glioma cells by the suicide gene was not adequate; (2) the vector used could not replicate, so gene transfer occurred within only a few celldistances from the producing cells; (3) the viral titer of the producer cells was not high enough, so a relatively large number of cells would need to be inoculated into the tumor; and (4) the proliferation rate of glioma in human brain was generally slower than that of the murine glioma cell lines which were used in the experimental models, so the transduction efficiency would be reduced. These factors indicated that this procedure would only be useful in the restricted treatment of small tumors, and/or if many inoculation tracts were used.
We previously reported rapid migration of genetically labeled murine RSV-M glioma cells after inoculation into normal murine brain and tumors. 6, 7 Since then we have been using this model as a basis for the potential treatment of glioma. In this report, we demonstrate that a bacterial ␤-galactosidase gene, lacZ, can be transduced into a large number of glioma cells by the implantation of high-titer retrovirus-producing fibroblast cells in the tumor, and that these cells are capable of migrating and moving within the tumor. Our data suggest that one must carefully reconsider the implantation site of the packaging cells (retrovirus-producing fibroblasts) in the tumor and the schedule of administration of ganciclovir (GCV), which kills HTK gene-bearing glioma cells, if we expect to reduce tumor mass using HTK-carrying retroviruses through the so-called by-stander effect.
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Results
Establishment of a fibroblast cell line producing high titers of lacZ-harboring virus The modified, amphotropic retrovirus packaging cell line, PAMP51, 11 was used for the production of high-titer retrovirus-producing cells. Replication-competent retroviruses (RCR) were not detected in PAMP51 packaging cells by the marker rescue assay. 11 Plasmid SV/pIP201
which contains the neomycin phosphotransferase (neo) gene driven by the 5Ј long terminal repeats (LTR) and the lacZ gene driven by the simian virus 40 (SV40) early promoter, was transfected into PAMP51 cells by using LipofectAMINE Reagent (GIBCO BRL, Gaithersburg, MD, USA) according to the protocol provided by the manufacturer. G418-resistant stable transformants, PAMP51/SV/pIP201 + , were obtained after G418 selection. Individual clones were selected by the limiting dilution technique. The retrovirus-producing clone with the highest titer produced 2 × 10 7 colony-forming units (c.f.u.)/ml. This clone was used for further experiments.
Distribution and pattern of X-gal-positive cells in murine brain LacZ-harboring virus producing cells (VPCs) were implanted into tumors formed in the murine brain. Mice were killed 3, 5, 10 and 14 days after the implantation of VPCs. Brain slices from these animals were then incubated with the X-gal reaction mixture and X-gal expression was followed over a period of 2 weeks. Three days after implantation, X-gal-positive cells were still found to be located near the inoculation site ( Figure 1a ). Tumor mass was over 5 mm in diameter. Five days later, the X-gal-positive area had become larger (Figure 1b) . Ten days later, about one-third of the area of the tumor mass including the inoculation site was X-gal positive (Figure 1c ). On the 14th day, about half of the tumor mass was X-gal positive (Figure 1d ).
The X-gal-positive cells were glioma cells transduced with the retrovirus which was secreted by the implanted VPCs in the tumor mass The brains of C3H/HeN mice were implanted with 1 × 10 5 RSV-M glioma cells. Ten days later the resulting tumors were implanted with 5 × 10 4 DiI-labeled lacZharboring VPCs. Two days later, the mice were killed. Brain slices from these mice were incubated with X-gal mixture and X-gal expression was followed using a light microscope (Figure 2a ). X-gal-positive cells were found only in the area close to the inoculated site and lay scattered apart. The slice was also observed with a fluorescent microscope (Figure 2b ). The DiI-positive red area appeared to be rounded in shape and this area corresponded to that of the implanted cells (arrow) in the tumor mass. These cells were not reactive for X-gal (Figure 2a) . The photographs suggest that the X-gal-positive cells were not the implanted VPCs but rather the glioma cells around the inoculation site of the VPCs. The reason why DiI-labeled VPCs were not reactive for X-gal might be because of promoter shut-off (see Discussion).
X-gal-positive glioma cells transduced by directly injecting lacZ-harboring retroviruses into the tumor mass The brains of C3H/HeN mice were implanted with 1 × 10 5 RSV-M glioma cells. Ten days later the resulting tumors were inoculated with 3 l of supernatant of the lacZ-harboring VPC (PAMP51/SV/pIP201 + ) culture containing the retrovirus. Three days later, the mice were killed and fixed. Brain slices from these mice were incubated with X-gal mixture and observed with a light microscope ( Figure 3 ). X-gal-positive glioma cells were found in the inoculation site and along the tumor margin. This supports the results shown in Figure 2 and confirms that the transduced glioma cells can migrate in the tumor.
Transduced glioma cells migrate inside the tumor mass
Higher magnification of Figure 1b allows visualization of the spindle-shaped, migrating X-gal-positive cells ( Figure  4 ). These cells are considered to be glioma cells transduced by the lacZ-harboring retroviruses which were secreted by the VPCs. They appear to be moving along the boundary of the inner surface of the tumor. Judging from this picture, the extension of the stained area (shown in Figure 1 ) would appear to be caused by these migrating glioma cells.
Preferential transduction of glioma cells located near the periphery of the tumor
The brains of C3H/HeN mice were implanted with 1 × 10 5 RSV-M glioma cells and 10 days later the resulting tumor mass was implanted with 5 × 10 4 Dil-labeled lacZharboring VPCs. Five days later, mice were killed and the brain slices were examined ( Figure 5a ). Red areas corresponding to the implanted VPCs were located near the boundary of the tumor (arrow). Adjacent slices were incubated with X-gal reaction mixture and examined ( Figure 5b ). X-gal-positive cells located close to the surface of the implanted site (arrow) appear more densely packed compared with the X-gal-positive cells located on the opposite side. A thick green belt (arrowheads) shows migration of glioma cells, which were transduced near the inner surface of the tumor mass, to distant sites along the margin of the tumor. This indicates that the peripheral region contains more mitotically active cells than the central region of the tumor, and that these cells tend to move towards the more peripheral regions of the tumor. The reason for this phenomenon is discussed below.
Discussion
Currently, several clinical trials using gene therapy are underway, and some have already yielded some preliminary results. So far, such clinical trials have mostly relied on the use of retroviral vectors because they provide a relatively safe system with no severe side effects. As there are few dividing cells around tumors in the brain, retroviruses represent one of the best vectors to transduce suicide genes such as the HTK gene selectively into tumor cells.
A shortcoming of the retroviral vector is its low transduction efficiency. To overcome this restriction, several approaches have been explored. One of the most promis- ing approaches is the injection of retrovirus-producing cells into the tumor mass with the hope that retrovirusproducing cells in the tumor will continuously secrete the retroviral vector for several days, thereby increasing the exposure of the tumor cells to the retroviral vector. This approach was validated by experiments in which fibroblast cells producing retroviruses carrying the lacZ gene were inoculated into gliomas of rat brain. 12 Histochemical evidence of lacZ gene transfer was seen in up to 10% of the glioma cells, while normal brain was not transduced. The HTK gene was transferred by a similar technique, and efficiencies of 10-70% were observed. 13 Culver et al 14 reported the elimination of microscopic brain tumors by GCV treatment after the stereotactic implantation of fibroblast cells producing HTK gene-carrying retroviruses. Transplantation of such cells into the human brain might present some risks, such as those linked with the possible presence of residual agents from the cell cultures, or host inflammatory responses to foreign antigens present in the xenogeneic cells. Also, xenogeneic fibroblast cells in human brain might survive for shorter times and/or express the transgene less efficiently compared with murine fibroblast cells in murine brain. However, the use of steroids or some other reagent should help to overcome this problem. The most recent clinical study realized in the National Institute of Health revealed that this clinical protocol was effective for small tumors and quite safe except for a small number of side effects. 5 Much effort has been expended in constructing new vectors that allow more efficient gene transduction and greater specificity. Some of these efforts have been directed towards obtaining the best promoter to express strongly the desired gene. Others attempted to perform minor modifications such as adding an enhancer to improve efficiency. We developed a vector named SV/pIP201 + which contains the neomycin phosphotransferase (neo) and the E.coli lacZ genes within two Moloney murine leukemia virus (MoMLV) long terminal repeats (LTRs). The simian virus 40 (SV40) early promoter controls the expression of the lacZ gene and the presence of an extended Psi packaging signal (Psi + ) gives a higher packaging efficiency. 15 We also developed a new packaging cell, PAMP51, which is derived from the fibroblast cell, PA317. This cell was introduced with polyoma early region. 11 When this vector was transfected into the PAMP51 packaging cell, the supernatant of the cloned retrovirus-producing cells with the highest titer gave 2 × 10 7 c.f.u./ml without the need for any helper virus. A so-called bystander effect has been reported. Tumor cells harboring the HTK gene die together with the surrounding cells after GCV treatment. This effect is believed to occur mainly through cell-cell contact between HTK-modified cells and unmodified wild-type cells. The transfer of phosphorylated GCV to adjacent cells is thought to be the main mechanism underlying this effect. This means that increased transduction efficiency will require a more even dispersion of virusproducing cells in the tumor. We have tried multiple
Figure 2 X-gal staining of brain slices 2 days after implantation of the tumors with DiI-labeled lacZ-harboring VPCs. (a) Observation with a light microscope shows a small group of X-gal-positive cells. This slice contains the inoculation site of the VPCs (arrow) at the edge of the tumor. The implanted DiI-labeled VPCs look slightly red. (b) Fluorescent microscopy detects a DiI-positive red area with a round shape (arrow). This area corresponds to the inoculated VPCs. (a) and (b) suggest that the X-gal-positive cells are not the inoculated VPCs but rather the glioma cells which encircle the inoculation site of the VPCs.
implantation of packaging cells into tumors formed in the brain but this has proved to be impractical.
In this study we have shown that the implantation of retrovirus-producing fibroblast cells into mouse brain glioma results in glioma cells expressing the lacZ gene carried by the retrovirus, and that these glioma cells are able to migrate within the tumor. The lacZ-expressing cells in Figure 1 appear to be true migrating glioma cells and not VPCs. In fact, our previous work revealed a difference between the migration of lacZ-VPCs and lacZ-transduced glioma cells within the tumor mass. 7 In addition, we have shown here that glioma cells directly transduced by the lacZ gene-bearing retrovirus in vivo could also migrate just like ex vivo transduced and transplanted glioma cells (Figure 3) . This supports the idea that lacZ expressing cells are true migrating glioma cells. Tamiya et al 16 expressing glioma cells around them. That means that implanted fibroblast packaging cells themselves do not migrate within the tumor, but stay at the inoculation site. Therefore, the lacZ gene expressing cells were not fibroblast packaging cells but glioma cells transduced by VPCs.
In Figures 2 and 5 , we showed that lacZ-transduced VPCs were X-gal negative, while the lacZ-transduced glioma cells around them were X-gal positive. This phenomenon can be explained by promoter shut-off, 17 although the mechanism has not been completely elucidated as yet. Transcription from the MoMLV promoter and the SV40 promoter is subject to suppression within a few days of transplantation of the lacZ-transduced VPCs back into mice. This transcription shut-off cannot be due to cell loss or gene deletion because transcription proficiency could be recovered when the transplanted cells were returned to in vitro conditions. 18 In our experiments, the beginning of the decline in transgene expression after implantation was a little early. However, shut-off of promoter activity may vary depending on the nature of the implantation zone.
The transduced glioma cells moved mainly along the tumor margin, with few cells migrating towards the center of the tumor. This phenomenon suggests that there are many more dividing cells at the peripheral regions of tumors than at the centers of tumors, and that mitotically active cell groups are inclined to wander away from the center towards the periphery of the tumor. Although we do not know the exact reason for this, tumor cell growth, in general, probably benefits from the rich supply of blood vessels found in the peripheral regions of tumors. Kruse et al 19 reported that genetically manipulated glioma cells migrate along perivascular spaces. Concerning clinical trials, our data suggest that the transplantation of virus-producing fibroblast cells inside and along the tumor margin might yield good results. Although the boundary of the GBM is usually ambiguous, sites of transplantation could be selected in the most peripheral part of the tumor. Practically speaking, GBM cells grow so rapidly that vessel growth sometimes cannot keep up with the feeding tumor cells, leading in some instances to a decay of the central part of the tumor and the formation of necrotic tissue which can be easily removed by surgery. This observation should help to define better where to transplant the virus-producing cells.
Our previous data demonstrated that a tumor consisting of wild-type glioma cells could be prevented from forming a larger mass by implanting HTK-modified glioma cells and administering GCV. Glioma cells inoculated 4 days after the initial injection took 4 days to catch up with the initially injected glioma cells by migration. A significant difference in tumor size was observed when GCV was administered between the first and fourth day after the second inoculation of glioma cells. 7 An analogous phenomenon may have occurred when GCV was administered after the virus-producing cells had been transplanted into the tumor. Thus, GCV treatment after the implantation of the fibroblast cells should be retarded until the infected glioma cells have time to migrate sufficiently, but the time should not be so long as to result in excessive tumor growth. 16 Two of the issues raised by our results may be applicable to clinical trials. One is that virus-producing fibroblast cells with a high titer are essential. The other is that the site of inoculation of virus-producing fibroblast cells is critically important. At the same time, the timing of GCV administration is likely to be pertinent when using virus-producing fibroblast cells carrying the HTK gene.
Our results should contribute to the content of future protocols for clinical trials using HTK gene-carrying retroviruses as therapeutic agents against malignant glioma.
Materials and methods
Cell culture and production of high-titer lacZ-harboring virus-producing cells A murine anaplastic glioma cell line, RSV-M glioma, 20 derived from C3H/HeN mice was provided by Dr T Kumanishi (Department of Neuropathology, Niigata University, Japan) and lacZ-harboring virus-producing cells were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO BRL, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; ICN Biomedicals Japan, Osaka, Japan), 100 units of penicillin per milliliter (Meiji Seika, Tokyo, Japan), and 100 g of streptomycin per milliliter (Meiji). PAMP51 is a modified amphotropic retrovirus packaging cell derived from PA317 (obtained from ATCC, Rockville, MD, USA) by introducing the polyomavirus early region. 11, 21 Cells grown on 6-cm Falcon 3001 dishes (Becton Dickinson, Oxnard, CA, USA) were transfected with the plasmid SV/pIP201 + , 11 which contains the lacZ gene driven by the SV40 early promoter, 22 by using LipofectAMINE Reagent (GIBCO). Cells (1 × 10 5 ) were seeded on Falcon 3001 dishes 1 day before transfection. Plasmid SV/pIP201 + (1 g) was mixed with 5 l of LipofectAMINE Reagent in 200 l of serum-free DMEM. After 1 h at room temperature, 800 l of serum-free DMEM was added. The mixture was layered on to the cells. Four hours later, the medium was replaced with 2 ml of fresh DMEM containing 10% FBS. Two days later, the medium was exchanged with fresh medium containing G418 (GIBCO) at a concentration of 1.0 mg/ml.
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G418-resistant stable transformants, PAMP51/SV/pIP201 + , were obtained after selection with G418 and cloned by a series of limiting dilution techniques. Titers of clones were estimated by counting bluestained X-gal-reactive NIH3T3 cells infected with the supernatant of each clone after 2 days. 24 The retrovirusproducing cell clone with the highest titer was selected and used for experiments.
Inoculation of glioma cells and lacZ-harboring virusproducing cells Eight-week-old female C3H/HeN mice weighing 17-22 g were anesthetized by intraperitoneal administration of pentobarbital (Abbott Laboratories, North Chicago, IL, USA) (50 mg/kg of body weight) and placed in a stereotactic apparatus (David Kopf Instruments, Tujunga, CA, USA). RSV-M glioma cells were trypsinized, washed twice with phosphate-buffered saline (PBS), and resuspended in PBS at a concentration of 1 × 10 5 cells/l. A head burr hole, 0.5 mm in diameter, was made 3 mm to the right and 1 mm anterior to the bregma with an electric drill after a mid-line skin incision. A glioma cell suspension, 1 × 10 5 cells in 1 l PBS, was injected by using a 10-l Hamilton syringe with a 26-gauge needle connected to a stereotactic arm through the burr hole. The cell suspension was inoculated at a depth of 3 mm from the dura (corresponding to the lateral area of the right striatum) over a period of more than 2 min. The needle was left in place for 3 min and then withdrawn slowly over 1 min. The skin wound was closed with a silk suture. LacZ-harboring virus-producing cells were injected in the same way.
Inoculation of glioma cells and lacZ-harboring virus
Instead of using the retrovirus-producing PAMP51/ SV/pIP201 + cells, mouse tumors were directly injected with the supernatant of VPCs containing the retrovirus. The RSV-M tumor mass, implanted and grown in the murine brain, was inoculated with 3 l of retrovirus supernatant in the same way as described above. The titer of the retrovirus supernatant was 2 × 10 7 c.f.u./ml.
Labeling of cells
Two milligrams of DiI (1,1Ј Dioctadecyl 3,3,3Ј,3Ј tetramethyl-indocarbocyanine perchlorate) (Molecular Probes, Eugene, OR, USA) was dissolved in 1 ml of ethanol, and 50 l of the solution was added directly to 5-ml medium of lacZ-harboring virus-producing cells in a 6-cm culture dish. After a 1 h incubation at 37°C in an incubator, the cells were trypsinized, washed twice with PBS and suspended in PBS at a concentration of 5 × 10 4 cells/l. These cells were used as labeled cells.
X-gal reaction of brain slices after the implantation of virus-producing fibroblasts into the tumor C3H/HeN mice were inoculated with 1 × 10 5 RSV-M glioma cells as described before. Ten days later, the RSV-M tumor mass of the mice was inoculated with 3 × 10 5 lacZ-harboring virus-producing fibroblast cells, PAMP51/SV/pIP201 + , using the same tract that had been used for the initial inoculation of glioma cells. Four mice were killed 3, 5, 10 and 14 days after the second inoculation and systemically perfused with 4% paraformaldehyde, 0.2% glutaraldehyde and 0.02% NP-40 in PBS. After post-fixation with the same fixative for 30 min, the brain was sliced into 200-m thick coronal sections with a microslicer (DTK-3000) (DOSAKA EM, Kyoto, Japan). The brain slices of these mice were rinsed twice in PBS with 1 mm MgCl 2 and incubated for 4 h at 37°C in an Xgal reaction mixture consisting of 0.1% X-gal, 0.01% sodium deoxycholate, 0.02% NP-40, 1 mm MgCl 2 , 5 mm K 3 (Fe(CN) 6 ), and 5 mm K 4 (Fe(CN) 6 ) in PBS.
Examination of migrating cells in the tumor mass formed in murine brain C3H/HeN mice were inoculated with 1 × 10 5 RSV-M glioma cells as described above. Ten days later, the RSV-M tumor mass of the mice was inoculated with 5 × 10 4 DiIlabeled lacZ-harboring virus-producing fibroblast cells, PAMP51/SV/pIP201 + , using the same tract that had been used for the initial inoculation of glioma cells. The mice were killed 2 or 5 days after the second inoculation, and perfused with the fixative in the same way as described above. Another mouse tumor was injected with 3 l of supernatant of the PAMP51/SV/pIP201 + cells containing the retrovirus instead of the lacZ-harboring virus-producing fibroblast cells. Three days later, the mice were killed and fixed in the same way. Their brains were sliced into 200-m thick coronal sections and observed both with a light microscope and with a fluorescent microscope. Some slices were examined after the X-gal reaction.
